Rituximab for the treatment of IgG4-related disease: Lessons from 10 consecutive patients

Medicine

Volumn 91, Issue 1, 2012, Pages 57-66

  Khosroshahi, Arezou ^a   Carruthers, Mollie N ^a   Deshpande, Vikram ^a   Unizony, Sebastian ^a   Bloch, Donald B ^a   Stone, John H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOGLOBULIN G; PREDNISONE; RITUXIMAB; TENOFOVIR;

ADULT; AGED; AORTITIS; ARTICLE; ASTHMA; AUTOIMMUNE PANCREATITIS; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; IMMUNOGLOBULIN G4 RELATED DISEASE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY DISEASE; LUNG DISEASE; LYMPHADENOPATHY; MALE; ORBIT DISEASE; PRIORITY JOURNAL; RETROPERITONEAL FIBROSIS; RETROSPECTIVE STUDY; RIEDEL GOITER; SCLEROSING CHOLANGITIS; SIALOADENITIS; SKIN NODULE; THYROIDITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; FIBROSIS; GLUCOCORTICOIDS; HUMANS; HYPERGAMMAGLOBULINEMIA; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INFLAMMATION; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PREDNISONE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84855352515     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0b013e3182431ef6     Document Type: Article

References (34)

1. Artz AS, Somerfield MR, Feld JJ, Giusti AF, Kramer BS, Sabichi AL, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol. 2010;28:3199-3202.
2. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11-21.
3. Chari ST, Smyrk TC, Levy MJ, Topazian MD, Takahashi N, Zhang L, et al. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol. 2006;4: 1010-1016. (Pubitemid 44118845)
4. Cheuk W, Chan JK. IgG4-related sclerosing disease: a critical appraisal of an evolving clinicopathologic entity. Adv Anat Pathol. 2010;17:303-332.
5. Church NI, Pereira SP, Deheragoda MG, Sandanayake N, Amin Z, Lees WR, et al. Autoimmune pancreatitis: clinical and radiological features and objective response to steroid therapy in a UK series. Am J Gastroenterol. 2007;102:2417-2425. (Pubitemid 47631797)
6. Dahlgren M, Khosroshahi A, Nielsen GP, Deshpande V, Stone JH. Riedel's thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. Arthritis Care Res (Hoboken). 2010;62:1312-1318.
7. Deshpande V, Khosroshahi A, Nielsen GP, Hamilos DL, Stone JH. Eosinophilic angiocentric fibrosis is a form of IgG4-related systemic disease. Am J Surg Pathol. 2011;35:701-706.
8. Ebbo M, Daniel L, Pavic M, Seve P, Hamidou M, Andres E, Burtey S, Chiche L, Serratrice J, Longy-Boursier M, Ruivard M, Haroche J, Godeau B, Beucher AB, Berthelot JM, Papo T, Pennaforte JL, Benyamine A, Jourde N, Landron C, Roblot P, Moranne M, Silvain C, Granel B, Bernard F, Veit V, Mazodier K, Bernit E, Rousset H, Boucraut J, Boffa JJ, Weiller PJ, Kaplanski G, Aucouturier P, Harle JR, Schleinitz N. IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. Medicine (Baltimore). 2012;91:49-56.
9. Ferri C, Govoni M, Calabrese L. The A, B, Cs of viral hepatitis in the biologic era. Curr Opin Rheumatol. 2010;22:443-450.
10. Geyer JT, Ferry JA, Harris NL, Stone JH, Zukerberg LR, Lauwers GY, et al. Chronic sclerosing sialadenitis (Kuttner tumor) is an IgG4-associated disease. Am J Surg Pathol. 2010;34:202-210.
11. Ghazale A, Chari ST. Optimising corticosteroid treatment for autoimmune pancreatitis. Gut. 2007;56:1650-1652. (Pubitemid 350206287)
12. Kamisawa T, Funata N, Hayashi Y, Eishi Y, Koike M, Tsuruta K, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol. 2003;38:982-984. (Pubitemid 37455786)
13. Kamisawa T, Okamoto A. Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastroenterol. 2006;41:613-625. (Pubitemid 44288524)
14. Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A, et al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009;58:1504-1507.
15. Kamisawa T, Takuma K, Egawa N, Tsuruta K, Sasaki T. Autoimmune pancreatitis and IgG4-related sclerosing disease. Nat Rev Gastroenterol Hepatol. 2010;7:401-409.
16. Kamisawa T, Yoshiike M, Egawa N, Nakajima H, Tsuruta K, Okamoto A. Treating patients with autoimmune pancreatitis: results from a long-term follow-up study. Pancreatology. 2005;5:234-238; discussion 238-240. (Pubitemid 40754743)
17. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56:3896-3908. (Pubitemid 350262316)
18. Khan ML, Colby TV, Viggiano RW, Fonseca R. Treatment with bortezomib of a patient having hyper IgG4 disease. Clin Lymphoma Myeloma Leuk. 2010;10:217-219.
19. Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum. 2010;62:1755-1762.
20. Khosroshahi A, Stone JH. A clinical overview of IgG4-related systemic disease. Curr Opin Rheumatol. 2011;23:57-66.
21. Khosroshahi A, Stone JH. IgG4-related systemic disease: the age of discovery. Curr Opin Rheumatol. 2011;23:72-73.
22. Khosroshahi A, Stone JH. Treatment approaches to IgG4-related systemic disease. Curr Opin Rheumatol. 2011;23:67-71.
23. Khosroshahi A, Stone JR, Pratt DS, Deshpande V, Stone JH. Painless jaundice with serial multi-organ dysfunction. Lancet. 2009;373:1494.
24. Liu Z, Davidson A. BAFF inhibition: A new class of drugs for the treatment of autoimmunity. Exp Cell Res. 2011;317:1270-1277.
25. Matsushita M, Ikeura T, Fukui T, Uchida K, Okazaki K. Refractory autoimmune pancreatitis: azathioprine or steroid pulse therapy? Am J Gastroenterol. 2008;103:1834; author reply 1834-1835.
26. Naitoh I, Nakazawa T, Ohara H, Sano H, Ando T, Hayashi K, et al. Autoimmune pancreatitis associated with various extrapancreatic lesions during a long-term clinical course successfully treated with azathioprine and corticosteroid maintenance therapy. Intern Med. 2009;48:2003-2007.
27. Okazaki K, Kawa S, Kamisawa T, Ito T, Inui K, Irie H, et al. Japanese clinical guidelines for autoimmune pancreatitis. Pancreas. 2009;38:849-866.
28. Otsuki M, Chung JB, Okazaki K, Kim MH, Kamisawa T, Kawa S, et al. Asian diagnostic criteria for autoimmune pancreatitis: consensus of the Japan-Korea Symposium on Autoimmune Pancreatitis. J Gastroenterol. 2008;43:403-408. (Pubitemid 351997876)
29. Rock B, Martins CR, Theofilopoulos AN, Balderas RS, Anhalt GJ, Labib RS, et al. The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem). N Engl J Med. 1989;320:1463-1469. (Pubitemid 19143712)
30. Smyrk TC. Pathological features of IgG4-related sclerosing disease. Curr Opin Rheumatol. 2011;23:74-79.
31. Stone JH, Khosroshahi A, Hilgenberg A, Spooner A, Isselbacher EM, Stone JR. IgG4-related systemic disease and lymphoplasmacytic aortitis. Arthritis Rheum. 2009;60:3139-3145.
32. Topazian M, Witzig TE, Smyrk TC, Pulido JS, Levy MJ, Kamath PS, et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2008;6:364-366. (Pubitemid 351318380)
33. van Vollenhoven RF, Emery P, Bingham CO III, Keystone EC, Fleischmann R, Furst DE, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37:558-567.
34. Zen Y, Nakanuma Y. IgG4-related disease: a cross-sectional study of 114 cases. Am J Surg Pathol. 2010;34:1812-1819.